Apollomics Announces $10 Million Private Placement Transaction

Rhea-AI Summary

Apollomics (Nasdaq: APLM) entered into definitive subscription agreements for a $10.0 million private placement with accredited investors. The transaction is expected to close on or about August 14, 2026, subject to customary conditions.

The private placement includes cash subscriptions for 533,334 Class A shares at $15.00 per share, for gross cash proceeds of about $8.0 million, and the automatic conversion of a $2.0 million unsecured convertible promissory note held by CEO Hung-Wen (Howard) Chen into 166,667 Class A shares at $12.00 per share. Certain executive officers and directors or their affiliates are participating in the cash portion. No placement agents or underwriters are involved, and no finder's fees or commissions are payable. The shares will be issued as unregistered, restricted securities under exemptions including Section 4(a)(2) and Rule 506 of Regulation D.

Positive

• Private placement raises $10.0 million in aggregate consideration
• Generates approximately $8.0 million in gross cash proceeds at $15.00 per share
• Converts $2.0 million of unsecured convertible debt into equity at $12.00 per share
• Insider participation from CEO, CFO, and COO affiliate aligns management with investors
• No placement agents or underwriters used; no finder's fees or commissions payable

Negative

• Issuance of up to 700,001 new Class A shares will increase share count
• All new shares are restricted securities subject to Rule 144 holding periods

News Explained

Up to 700,001 shares would dilute existing ownership, while only approximately $8.0 million of the $10.0 million transaction is new cash.

Apollomics has entered definitive agreements, but the planned issuance of up to 700,001 Class A shares remains pending a closing expected on or about August 14, 2026; if completed, issuing those additional shares would reduce existing holders’ percentage ownership absent offsetting changes.

This is a private placement, meaning securities are sold to selected investors outside a public offering. Its stated consideration combines approximately $8.0 million of new cash with the automatic conversion of a $2.0 million promissory note, so the full approximately $10.0 million headline amount is not all new cash for the company.

The shares will be unregistered and restricted, and the release says they cannot be offered or sold in the United States without registration or an applicable exemption.

Market Context

Historical event 1074412 produced a 7.32% 24-hour gain after a Nasdaq deficiency notice, adding a us...

Analysis

Historical event 1074412 produced a 7.32% 24-hour gain after a Nasdaq deficiency notice, adding a useful context comparison. The active F-3/A is a resale registration, and low short positioning remains a risk qualifier to monitor.

Key Figures

Gross consideration: approximately $10.0 million Expected closing: August 14, 2026 Shares issued: up to 700,001 Class A shares +5 more

8 metrics

Gross consideration approximately $10.0 million Private placement

Expected closing August 14, 2026 Subject to customary closing conditions

Shares issued up to 700,001 Class A shares Private placement

Cash subscription shares 533,334 Class A shares Cash investment tranche

Cash purchase price $15.00 per share Cash investment tranche

Cash proceeds approximately $8.0 million Before fees and expenses

Note principal $2.0 million Automatic conversion of unsecured convertible promissory note

Conversion terms $12.00 per share; 80% of cash purchase price; 166,667 shares Note conversion tranche

Historical Context

4 past events · Latest: Jul 13 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 13	Nasdaq compliance	Positive	-25.0%	Regained compliance after meeting Nasdaq's minimum market-value requirement.
Jun 24	Nasdaq deficiency notice	Negative	+7.3%	Received a minimum market-value deficiency notice and provided vebreltinib rights updates.
Apr 27	Earnings report	Negative	-0.7%	Reported a net loss and limited cash despite revenue and clinical program updates.
Apr 01	Bridge financing	Negative	-7.1%	Entered a convertible bridge financing with the chief executive officer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

APLM previously diverged from headline direction on Nasdaq-related news, while its prior financing announcement aligned with a negative price reaction.

Key Terms

private placement, convertible promissory note, accredited investors, rule 506, +1 more

5 terms

private placement financial

"entered into definitive subscription agreements for a private placement transaction"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

convertible promissory note financial

"outstanding $2.0 million principal amount of that certain unsecured Convertible Promissory Note"

A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.

accredited investors financial

"with certain accredited investors (the “Investors”)"

Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.

rule 506 regulatory

"Rule 506 of Regulation D promulgated thereunder"

A Securities and Exchange Commission rule that lets companies sell securities without registering them with the SEC when they meet certain conditions, commonly used for private placements. It allows issuers to raise unlimited capital from accredited investors and, in some versions, a small number of knowledgeable non‑accredited investors; one version also permits public advertising if the seller takes steps to verify investor credentials. For investors, it signals a private offering with lighter disclosure and different protections than a public stock sale, similar to buying into a private club rather than a publicly traded marketplace.

rule 144 regulatory

"customary holding periods under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions.

The Private Placement comprises the issuance of an aggregate of up to 700,001 Class A ordinary shares, par value $0.01 per share, of the Company (the “Class A Shares”) under the following tranches:

• Cash Investment: Cash subscriptions for an aggregate of 533,334 Class A Shares at a purchase price of $15.00 per share, generating aggregate gross cash proceeds of approximately $8.0 million before fees and expenses.
  
  
• Note Conversion: The automatic conversion of the outstanding $2.0 million principal amount of that certain unsecured Convertible Promissory Note, dated March 30, 2026, held by Mr. Hung-Wen (Howard) Chen, the Company’s Chairman and Chief Executive Officer. Pursuant to the terms of the Note, the conversion price is set at $12.00 per share, representing 80% of the purchase price paid by cash investors in the PIPE Transaction, resulting in the issuance of 166,667 Class A Shares at closing.
  
  

The cash portion of the Private Placement includes participation from certain unaffiliated accredited investors, as well as several of the Company's executive officers and directors (or their affiliates), including Chief Executive Officer Hung-Wen (Howard) Chen, Chief Financial Officer Peter Kuan-How Lin, and Maxpro Investment Co., Ltd. (an affiliate of Chief Operating Officer Yi-Kuei (Alex) Chen).

No placement agents or underwriters were utilized in connection with the Private Placement, and no finder's fees or commissions are payable.

The Class A Shares to be issued in the Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction's securities laws, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder, or under any state securities laws. The Company relied on this exemption from registration based in part on representations made by the Investors. The securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Investors have agreed that all Class A Shares issued at closing will be restricted securities subject to customary holding periods under Rule 144.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Apollomics Inc., nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.

For more information, please visit  www.apollomicsinc.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2025, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.

Investor Contacts
Peter Lin, Chief Financial Officer
Apollomics, Inc.
1-650-209-4055
peter.lin@apollomicsinc.com

Peter Vozzo
ICR Healthcare
1-443-213-0505
Peter.Vozzo@icrhealthcare.com   

FAQ

What is the size of the Apollomics (APLM) private placement announced on August 11, 2026?

Apollomics plans a private placement with aggregate gross consideration of $10.0 million. According to Apollomics, this consists of roughly $8.0 million in cash subscriptions and the $2.0 million automatic conversion of an existing unsecured convertible promissory note into Class A ordinary shares.

How many new shares will be issued in the Apollomics (APLM) August 2026 private placement and at what prices?

Apollomics expects to issue up to 700,001 Class A shares. According to Apollomics, 533,334 shares will be sold for cash at $15.00 per share and 166,667 shares will be issued on note conversion at a price of $12.00 per share.

When is the Apollomics (APLM) $10 million private placement expected to close?

The private placement is expected to close on or about August 14, 2026. According to Apollomics, closing remains subject to the satisfaction of customary closing conditions that typically apply to similar private financing transactions with accredited investors.

Who is participating in the Apollomics (APLM) private placement, and does management take part?

The private placement involves certain accredited investors, including unaffiliated investors and insiders. According to Apollomics, participants include CEO Hung-Wen (Howard) Chen, CFO Peter Kuan-How Lin, and Maxpro Investment, an affiliate of COO Yi-Kuei (Alex) Chen, alongside other accredited investors.

How is the Apollomics (APLM) CEO’s convertible note being treated in this private placement?

A $2.0 million unsecured convertible promissory note held by the CEO will automatically convert. According to Apollomics, the note converts into 166,667 Class A shares at $12.00 per share, equal to 80% of the $15.00 cash purchase price in this transaction.

Are the new Apollomics (APLM) shares registered and freely tradable after the August 2026 private placement?

The new Class A shares will be unregistered and restricted. According to Apollomics, issuance relies on exemptions including Section 4(a)(2) and Rule 506 of Regulation D, and the investors agreed the shares will be restricted securities subject to customary Rule 144 holding periods.

Does Apollomics (APLM) pay any fees or commissions in this $10 million private placement?

Apollomics does not expect to pay placement fees or commissions for this offering. According to Apollomics, no placement agents or underwriters were engaged, and no finder's fees or commissions are payable in connection with the private placement transaction.